With around 25% of adults being afraid of needles, it can make it difficult for a good portion of the population to get vaccinations, a blood test, or an IV drip put in
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzk M, PIONEER 1 Investigators
The benefit of starting gene therapy with sickle cell disease is that we are starting with mutated genes
To bridge the preclinicalclinical gap, three concrete translational pathways are proposed: (1) Biomarker validation: Conduct prospective human cohort studies to verify preclinical biomarkers (e.g., GSDMD-NT for pyroptosis, HMGB1 for inflammation, MDA for lipid peroxidation, ferritin for ferroptosis) in serum and liver biopsies of EHS/CHS patients, establishing their diagnostic (early liver injury detection) and prognostic (MODS progression prediction) utility [59, 89]
The manufacturer claimed that there was not sufficient data to establish a causal connection between the use of a GLP-1 receptor agonist (semaglutide) and NAION
